Intensity Therapeutics Inc (INTS)
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for cancer with both regional and systemic activity in the United States. The company’s lead candidate, INT230-6, is being evaluated in Phase 3 clinical studies for soft tissue sarcoma and in Phase 2 trials for neoadjuvant and metastatic triple-negative breast cancer. Incorporated in 2012 and based in Shelton, Connecticut, Intensity Therapeutics trades on the NASDAQ as common stock under the symbol INTS.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-INTS
|
$5.29
|
28.7% Upside
|
Undervalued
|
$19.33
|
370.4% Upside
|
Bargain
|
Fair
|
0.0%
|
November 17, 2026
|
1.5x
|
13.419 M
|
3.985 M
|
0.7%
|
93.1%
|
-9.2
|
80.2%
|
